REG - Futura Medical PLC - Total Voting Rights

Futura MedicalAnnouncement

01/02/2019 07:00

RNS Number : 7519O
Futura Medical PLC
01 February 2019
 



Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 204,660,267 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 204,660,267 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.




For further information please contact:           


For media enquiries please contact:




 


 




Futura Medical plc


Optimum Strategic Communications




Angela Hildreth, FD/COO


Mary Clark/ Hollie Vile/ Ellie Blackwell              




investor.relations@futuramedical.com


Email: futuramedical@optimumcomms.com




www.futuramedical.com


Tel: +44 (0) 203 950 9144




Tel: +44 (0) 1483 685 670


 




 


 




Nominated Advisor/Broker


 




N+1 Singer


 




Aubrey Powell/ Ben Farrow (Corporate Finance)


 




Tom Salvesen/ Mia Gardner (Corporate Broking)


 




Tel: +44 (0) 20 7496 3000


 




 
Notes to Editors
 
Futura Medical plc
 
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
 
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 
 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRZMGFMNMVGLZM